Home » Topics » Regulatory » EMA

EMA
RSS

Santhera anticipates negative CHMP opinion on appeal for MAA for Raxone

Jan. 25, 2018

U.S. priority review and E.U. accelerated assessment granted for Kymriah

Jan. 17, 2018

EMA accepts Evenity MAA in osteoporosis

Jan. 8, 2018

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Jan. 8, 2018

EMA accepts CMA application for avacopan for ANCA-associated vasculitis

Jan. 4, 2018

Cascadian Therapeutics receives pediatric investigation plan waiver from EMA for tucatinib

Jan. 3, 2018

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

Dec. 29, 2017

EMA committee recommends against approval of Aplidin for multiple myeloma.

Dec. 19, 2017

Bristol-Myers Squibb's Yervoy recommended for approval in Europe for pediatric melanoma

Dec. 19, 2017

EMA committee recommends approval of Alkindi for pediatric adrenal insufficiency

Dec. 18, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...